Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction

Area of Science:

• Cardiovascular medicine
• Pharmacology
• Vascular biology

Background:

• Cardiovascular diseases stem from vascular dysfunction, characterized by increased sensitivity to vasoconstrictors and reduced vasodilators like nitric oxide (NO) and prostacyclin (PGI2).
• Endothelium-derived hyperpolarization (EDH) pathways are also impaired in cardiovascular dysfunction.
• Serelaxin, a recombinant human relaxin, is a new vasoactive drug with demonstrated utility in acute heart failure.

Purpose of the Study:

• To review the role of endogenous relaxin in maintaining cardiovascular (CV) homeostasis.
• To discuss the vascular effects and mechanisms of action of serelaxin compared to other vasodilators.
• To explain the therapeutic potential of serelaxin for vascular dysfunction in various CV diseases, especially those involving oxidative stress.

Main Methods:

• Literature review encompassing the role of endogenous relaxin in CV homeostasis.
• Analysis of vascular effects and mechanisms of action of serelaxin.
• Discussion of serelaxin's efficacy in vascular dysfunction associated with CV diseases and oxidative stress.

Main Results:

• Endogenous relaxin plays a role in CV homeostasis.
• Serelaxin exhibits vasodilatory effects through mechanisms distinct from or complementary to other vasodilators.
• Serelaxin demonstrates potential in treating vascular dysfunction, particularly when linked to oxidative stress.

Conclusions:

• Serelaxin is a promising therapeutic agent for vascular dysfunction in cardiovascular diseases.
• Its vasodilatory properties and potential to counteract oxidative stress-related damage are key benefits.
• Further research supports serelaxin's role in managing complex cardiovascular conditions.